Skip to main content
Top
Published in: Familial Cancer 2/2023

Open Access 23-11-2022 | Melanoma | Review

Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with lynch syndrome: a systematic review

Authors: Shahram Aziz, Hazel O’Sullivan, Kara Heelan, Afrina Alam, Terri P. McVeigh

Published in: Familial Cancer | Issue 2/2023

Login to get access

Abstract

A subset of patients with Lynch Syndrome demonstrates cutaneous manifestations of the disorder. Characterization of these Lynch-related skin lesions could help in early recognition of patients with Lynch Syndrome. A broad search of the literature on OVID Medline and Embase was carried out to capture papers reporting cutaneous manifestations in Lynch Syndrome patients. The results were uploaded into Mendeley reference management software. The PRISMA workflow was used in the literature selection process. In this systematic review, data were collected from 961 cases from 413 studies, including 380 molecularly confirmed Lynch Syndrome cases. The main skin lesions were: Sebaceous adenomas (43%), sebaceous carcinomas (27%), keratoacanthomas (16%), sebaceomas (13%), squamous cell carcinomas (23%), and basal cell carcinomas (10%). MSH2 variants were the most common underlying genotype (72%). Assessment of mismatch repair by immunohistochemistry, microsatellite instability analysis, or both were performed on 328 skin lesions from 220 (58%) molecularly confirmed cases. In those skin lesions, 95% of Immunohistochemistry and 90% of the microsatellite instability test results were concordant with the underlying genotype. Sebaceous skin lesions are well-recognised phenotypic features of Lynch Syndrome. Our results show that squamous and basal cell carcinomas are relatively common in patients with Lynch syndrome; however, available evidence cannot confirm that Lynch syndrome is causal. Immunohistochemistry and/or microsatellite instability testing of skin tumours in patients with a family history of Lynch Syndrome-associated cancers may be a useful approach in identifying patients requiring referral to Clinical Genetics and/or consideration of germline genetic testing for Lynch Syndrome.
Appendix
Available only for authorised users
Literature
3.
go back to reference Da Silva FC, De Oliveira LP, Santos EM, Nakagawa WT, Junior SA, Valentin MD et al (2010) Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer. Springer 9(4):563–570. https://doi.org/10.1007/s10689-010-9373-2CrossRef Da Silva FC, De Oliveira LP, Santos EM, Nakagawa WT, Junior SA, Valentin MD et al (2010) Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer. Springer 9(4):563–570. https://​doi.​org/​10.​1007/​s10689-010-9373-2CrossRef
10.
12.
17.
go back to reference Manonukul J, Kajornvuthidej S (2010) Sebaceous neoplasms in Siriraj Hospital, Mahidol University: a 9-year-retrospective study. J Med Assoc Thai 93(8):978–991PubMed Manonukul J, Kajornvuthidej S (2010) Sebaceous neoplasms in Siriraj Hospital, Mahidol University: a 9-year-retrospective study. J Med Assoc Thai 93(8):978–991PubMed
Metadata
Title
Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with lynch syndrome: a systematic review
Authors
Shahram Aziz
Hazel O’Sullivan
Kara Heelan
Afrina Alam
Terri P. McVeigh
Publication date
23-11-2022
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2023
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-022-00319-8

Other articles of this Issue 2/2023

Familial Cancer 2/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine